M Marre
Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes
Mu B, Sterner M, Tang M, Tarnow L, Tuomi T, van't Riet E, van Leeuwen N, Varga T, Vestmar M, Walker M, Wang B, Wang Y, Slagboom P, Nielsen A, Nijpels G, Nilsson P, Palmer C, Rayner N, Renström F, Ribel-Madsen R, Robertson N, Rolandsson O, Rossing P, Schwartz T, Wu H, Xi F, Yengo L, Laakso M, Groop L, Christensen C, Brandslund I, Lauritzen T, Witte D, Linneberg A, Jørgensen T, Hansen T, Wang J, Nielsen R, McCarthy M, Froguel P, Yu C, Zhang X, Zhang J, Zhang Q, Zhang W, Zheng H, Zhou Y, Altshuler D, 't Hart L, Franks P, Balkau B, Pedersen O, Morris A, Albrechtsen A, Ladenvall C, Cauchi S, Stančáková A, Andersen G, Astrup A, Banasik K, Bennett A, Bolund L, Charpentier G, Chen Y, Dekker J, Morris A, Skotte L, Grarup N, Li Y, Sparsø T, Tian G, Cao H, Jiang T, Kim S, Korneliussen T, Li Q, Nie C, Wu R, Doney A, Dorkhan M, Forsen T, Kuusisto J, Lajer M, Lantieri O, Li W, Liang H, Liao Q, Liu X, Ma T, Ma X, Manijak M, Marre M, Kristiansen K, Justesen J, Frayling T, Groves C, Gui Y, Hallmans G, Hattersley A, He K, Hitman G, Holmkvist J, Huang S, Jiang H, Jin X, Mokrosiński J. Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. Diabetologia 2012; 56:298-310.
19.11.2012Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes
19.11.2012Diabetologia 2012; 56:298-310
Mu B, Sterner M, Tang M, Tarnow L, Tuomi T, van't Riet E, van Leeuwen N, Varga T V, Vestmar M A, Walker M, Wang B, Wang Y, Slagboom P E, Nielsen A A, Nijpels G, Nilsson P, Palmer C N A, Rayner N W, Renström Frida, Ribel-Madsen R, Robertson N, Rolandsson O, Rossing P, Schwartz T W, Wu H, Xi F, Yengo L, Laakso M, Groop L, Christensen C, Brandslund I, Lauritzen T, Witte D R, Linneberg A, Jørgensen T, Hansen T, Wang J, Nielsen R, McCarthy M I, Froguel P, Yu C, Zhang X, Zhang J, Zhang Q, Zhang W, Zheng H, Zhou Y, Altshuler D, 't Hart L M, Franks P W, Balkau B, Pedersen O, Morris A D, Albrechtsen A, Ladenvall C, Cauchi S, Stančáková A, Andersen G, Astrup A, Banasik K, Bennett A J, Bolund L, Charpentier G, Chen Y, Dekker J M, Morris A P, Skotte L, Grarup N, Li Y, Sparsø T, Tian G, Cao H, Jiang T, Kim S Y, Korneliussen T, Li Q, Nie C, Wu R, Doney A S F, Dorkhan M, Forsen T, Kuusisto J, Lajer M, Lantieri O, Li W, Liang H, Liao Q, Liu X, Ma T, Ma X, Manijak M P, Marre M, Kristiansen K, Justesen J M, Frayling T M, Groves C J, Gui Y, Hallmans G, Hattersley A T, He K, Hitman G A, Holmkvist J, Huang S, Jiang H, Jin X, Mokrosiński J
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
Marre M, Colagiuri S, Le Thi T, Zdravkovic M, Strand J, Kamaruddin N, Bebakar W, Brändle M, Shaw J, LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic medicine : a journal of the British Diabetic Association 2009; 26:268-78.
01.03.2009Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
01.03.2009Diabetic medicine : a journal of the British Diabetic Association 2009; 26:268-78
Marre M, Colagiuri S, Le Thi T D, Zdravkovic M, Strand J, Kamaruddin N A, Bebakar W M W, Brändle Michael, Shaw J, LEAD-1 SU study group